EXHIBIT 7

TRANSACTION GRANTED EARLY TERMINATION—Continued

ET date	Trans No.	ET req status	Party name
		G	Stitching LA Fondation Andre Cointreau.
		G	Le Cordon Bleu International B.V.
18-AUG-09	20090648	G	McAfee, Inc.
		G	MX Logic, Inc.
		G	MX Logic, Inc.
20-AUG-09	20090427	G	Arch Coal, Inc.
		G	Rio unto plc.
		G	Jacobs Ranch Coal LLC.
	20090448	G	Oracle Corporation.
		G	Sun Microsystems, Inc.
		G	Sun Microsystems, Inc.
21-AUG-09	20090655	G	Sprint Nextel Corporation.
		G	Virgin Mobile USA, Inc.
		G	Virgin Mobile USA, Inc.
	20090657	G	ArcLight Energy Partners Fund III, L.P.
		G	PPL Corporation.
		G	PPL Maine, LLC.
	20090661	G	ArcLight Energy Partners Fund IV, L.P.
		G	PPL Corporation.
		G	PPL Maine, LLC.
	20090665	G	Targa Resources Partners LP.
		G	Targa Resources Investments Inc.
		G	Targa LSNG GP LLC.
		G	Targa LSNG LP.
		G	Targa Downstream GP LLC.
		G	Targa Downstream LP.
24-AUG-09	20090647	G	Aetna Inc.
		G	Psychiatric Solutions, Inc.
		G	Horizon Behavioral Services, LLC.
	20090653	G	Manulife Financial Corporation.
		G	PPL Corporation.
		G	PPL Edgewood Energy, LLC.
		G	PPL Shoreham Energy, LLC.
	20090654	G	Electric Power Development Co., Ltd.
		G	PPL Corporation.
		G	PPL Edgewood Energy, LLC.
		G	PPL Shoreham Energy, LLC.
25-AUG-09	20090664	G	Sentara Healthcare.
		G	Potomac Hospital Foundation.
		G	Potomac Hospital Corporation of Prince William.
	20090645	G	Iochpe-Maxion S.A.
		G	ArvinMeritor, Inc.
		G	ArvinMeritor OE, LLC.
		G	Meritor LVS S.A. de C.V.
		G	Servicios Corporativos ArvinMeritor, S.A. de C.V.
		G	Meritor Comercio Industria de Sistemas Automotivos Ltda.
28-AUG-09	20090672	G	JPMorgan Chase & Co.
		G	ArthroCare Corporation.
		G	ArthroCare Corporation.
	20090676	G	Noble Group Limited.
		G	SemGroup, L.P.-Debtor-in-Possession.
		G	SemFuel, L.P.-Debtor-in-Possession.
01-SEP-09	20090626	G	Kurosawa B.V.
		G	William B. Dunavant, Jr.
		G	Dunavant Enterprises, Inc.
	20090677	G	Frontier Communications Corporation.
		G	Verizon Communications Inc.
		G	New Communications Holdings, Inc.
	20090687	G	Inverness Medical Innovations, Inc.
		G	Free & Clear, Inc.
		G	Free & Clear, Inc.
02-SEP-09	20090679	G	LS Power Equity Partners II, L.P.
		G	Dynegy, Inc.
		G	Sandy Creek Services, LLC.
		G	Riverside Generating Company, L.L.C.
		G	Renaissance Power, LLC.
		G	Bridgeport Energy LLC.
		G	Bluegrass Generation Company, L.LC.
		G	Dynegy Sandy Creek Holdings, LLC.
	20090680	G	LS Power Equity Partners, L.P.
		G	Dynegy, Inc.

TRANSACTION GRANTED EARLY TERMINATION—Continued

ET date	Trans No.	ET req status	Party name
		G	Tilton Energy LLC.
		G	Griffith Energy LLC.
		G	Dynegy Arlington Valley, LLC.
		G	Rocky Road Power, LLC.
	20090690	G	General Motors Company.
		G	Delphi Corporation.
		G	DIP Holdco LLP.
03–SEP–09	20090401	G	Fidelity National Information Services, Inc.
		G	Metavante Technologies, Inc.
		G	Metavante Technologies, Inc.
04–SEP–09	20090697	G	Electric Power Development Co., Ltd.
		G	General Electric Company.
		G	Birchwood Power Partners, L.P.
	20090702	G	Joe and Marlene Ricketts Grandchildren's Trust.
		G	Tribune Company.
		G	Chicago Baseball Holdings, LLC.
	20090704	G	STG III, L.P.
		G	MSC.Software Corporation.
		G	MSC.Software Corporation.

FOR FURTHER INFORMATION CONTACT: Sandra M. Peay, Contact Representative, or Renee Hallman, Contact Representative, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H–303, Washington, DC 20580, (202) 326–3100.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. E9–25377 Filed 10–21–09; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2009–N–0474]

Agency Information Collection Activities; Proposed Collection; Comment Request; Inspection by Accredited Persons Program Under the Medical Device User Fee and Modernization Act of 2002

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the publication of the criteria FDA intends to use to accredit third parties to conduct inspections of eligible manufacturers of class II or class III medical devices.

DATES: Submit written or electronic comments on the collection of information by December 21, 2009.

ADDRESSES: Submit electronic comments on the collection of information to *http://www.regulations.gov*. Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of Information Management (HFA–710), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–796–3793.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. "Collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Inspection by Accredited Persons Program Under the Medical Device User Fee and Modernization Act of 2002; FD&C Act, Section 704(g) (OMB Control Number 0910–0510)—Extension

The Medical Device User Fee and Modernization Act of 2002 (MDUFMA) (Public Law 107–250) was signed into law on October 26, 2002. Section 201 of MDUFMA adds a new paragraph "g" to section 704 of the Federal, Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 374), directing FDA to accredit third parties (accredited persons (APs) to conduct inspections of eligible manufacturers of class II or class III devices. This is a voluntary program.